We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

88 hedge funds and large institutions have $125M invested in Jounce Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 20 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more call options, than puts

Call options by funds: $448K | Put options by funds: $216K

90% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 20

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

12% less funds holding

Funds holding: 100 → 88 (-12)

38% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 26

43% less capital invested

Capital invested by funds: $221M → $125M (-$95.1M)

Holders
88
Holders Change
-12
Holders Change %
-12%
% of All Funds
1.94%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
16
Increased
38
Reduced
20
Closed
26
Calls
$448K
Puts
$216K
Net Calls
+$232K
Net Calls Change
+$195K

Top Buyers

Rank Fund Capital Flow
1
AQR Capital Management
AQR Capital Management
Connecticut
+$3.58M
2
Renaissance Technologies
Renaissance Technologies
New York
+$1.67M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$1.63M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.61M
5
ZIM
Zacks Investment Management
Illinois
+$1.35M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.88M
2
OAM
Oxford Asset Management
United Kingdom
-$1.76M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.75M
4
Marshall Wace
Marshall Wace
United Kingdom
-$1.25M
5
Two Sigma Investments
Two Sigma Investments
New York
-$1.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
Mariner
26
Mariner
Kansas
$710K +$860K +149,397 New
Verition Fund Management
27
Verition Fund Management
Connecticut
$696K +$844K +146,612 New
EIM
28
Essex Investment Management
Massachusetts
$514K – – –
SEI Investments
29
SEI Investments
Pennsylvania
$507K +$394K +68,421 +178%
SO
30
STRS Ohio
Ohio
$501K +$216K +37,600 +55%
Bank of Montreal
31
Bank of Montreal
Ontario, Canada
$499K +$631K +109,638 +4,901%
QI
32
QS Investors
New York
$480K – – –
CAM
33
Congress Asset Management
Massachusetts
$439K +$532K +92,470 New
Goldman Sachs
34
Goldman Sachs
New York
$380K -$178K -31,004 -28%
Wells Fargo
35
Wells Fargo
California
$351K +$103K +17,911 +32%
Axa
36
Axa
France
$350K – – –
Prudential Financial
37
Prudential Financial
New Jersey
$335K -$162K -28,206 -29%
N
38
Nuveen
North Carolina
$323K +$57.3K +9,961 +17%
Millennium Management
39
Millennium Management
New York
$314K +$10.6K +1,837 +3%
PP
40
PDT Partners
New York
$294K +$280K +48,700 +367%
SFM
41
Systematic Financial Management
New Jersey
$267K -$56.4K -9,800 -15%
Los Angeles Capital Management
42
Los Angeles Capital Management
California
$251K +$305K +52,926 New
AllianceBernstein
43
AllianceBernstein
Tennessee
$238K +$46.6K +8,100 +19%
Two Sigma Advisers
44
Two Sigma Advisers
New York
$235K -$395K -68,700 -58%
Federated Hermes
45
Federated Hermes
Pennsylvania
$235K +$269K +46,653 +1,608%
GCP
46
GSA Capital Partners
United Kingdom
$229K +$277K +48,169 New
Morgan Stanley
47
Morgan Stanley
New York
$210K -$17.9K -3,102 -7%
First Manhattan
48
First Manhattan
New York
$209K – – –
LPL Financial
49
LPL Financial
California
$203K +$91.5K +15,890 +59%
Citadel Advisors
50
Citadel Advisors
Florida
$198K +$174K +30,230 +260%
1
2
3 4 5

JNCE Hedge Fund Activity: Q1 2020 in Review

88 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q1 2020, worth a combined $125M — down 43% from $221M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of JNCE and 16 opened new positions — a net loss of 10 holders — while 20 trimmed existing stakes and 38 added.

The largest buyer was AQR Capital Management, opening a new position worth an estimated $3.58M. The largest seller was Fidelity Investments, cutting an estimated $3.88M.

  • 88 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q1 2020, down from 100 in Q4 2019.
  • Funds reported $125M of Jounce Therapeutics, Inc. Common Stock stock for Q1 2020, down 43% quarter-over-quarter.
  • 16 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q1 2020 and 26 closed out, a net change of -10 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q1 2020 was AQR Capital Management, an estimated $3.58M added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q1 2020 was Fidelity Investments, an estimated $3.88M sold.

Based on aggregated 13F filings for Q1 2020.